Target Audience

This program has been designed by a multidisciplinary faculty and the content is pertinent to the entire cancer care team, including community-based and academic physicians, nurses, physician assistants, trainees and researchers.

Learning Objectives: General Sessions

Upon completion of this activity, participants should be better able to:

  • Summarize the role of the immune system in tumor biology and how current immunotherapeutic approaches exploit these processes.
  • Assess the latest clinical advances regarding the use of immunotherapies and targeted therapies in various solid tumors and hematologic malignancies.
  • Determine how immunotherapy and targeted therapy fit into existing treatment pathway paradigms in various solid tumors and hematologic malignancies.
  • Examine paradigms for the use of immunotherapies with each other or alternative treatment modalities for cancer management.
  • Review strategies for the recognition and management of immune-mediated adverse events.
  • Describe emerging challenges associated with the use of immunotherapies and targeted therapies for cancer management.

Learning Objectives: Thursday CME Breakfast Symposium

Upon completion of this activity, participants should be better able to:

  • Implement treatment paradigms for patients with advanced melanoma that reflect that latest evidence regarding long-term outcomes.
  • Assess the latest evidence regarding the use of checkpoint inhibitors in patients with melanoma brain metastases and the resulting clinical implications.

Learning Objectives: Friday CME Breakfast Symposium

Upon successful completion of the activities, participants should be better able to:

  • Identify patients with HCC who may benefit from new agents in the first-line setting.
  • Assess the latest evidence regarding combination approaches for the management of patients with HCC.
  • Select treatment for patients with HCC based on the latest clinical evidence.

Learning Objectives: Friday CME Lunch Symposium

Upon successful completion of the activities, participants should be better able to:

  • Assess the latest data regarding the impact of checkpoint inhibitors as monotherapies or in combinations with chemotherapies for the first-line management of patients with advanced NSCLC.
  • Select treatment for patients with NSCLC based on the latest clinical evidence as well as patient and tumor characteristics.
  • Use checkpoint inhibitors for patients with SCLC in accordance with the latest clinical evidence and recommendations.
This continuing medical education activity is provided by

HemOnc Today New York 2019 is supported, in part, by educational grants from Bristol-Myers Squibb; Celgene Corporation; Eisai Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Prometheus Laboratories, Inc.

ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 19.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

NOTICE: Faculty, topics, program schedule and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.